GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Avacta Group AVCT.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

59.00p

-2.48%

Close of 20 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Avacta Group — daily AVCT

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Avacta Group on TradingView ↗
Market value
£203.3m
Last close × shares
Volume
2.1m
Shares, 20 Nov 2026

About Avacta Group

Its shares trade on LSE under the ticker AVCT.L. It has been listed since 8 September 2003. In the fiscal year to 31 December 2024, it reported revenue of £113,000 and a net loss of £52.8m. At that date it held total assets of £48.3m and shareholders' equity of £9.3m.

Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies. The company is headquartered in Wetherby, West Yorkshire. The company went IPO on 2003-09-08. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Figures and description from our data supplier, not checked against the company's own report.

More about Avacta Group →

How it makes its money

Revenue, year to 31 Dec 2021

  • Computex [Member] £96.9m · 3977.7%
  • Consolidated [Member] £20.0m · 822.7%
  • Kandy [Member] £20.0m · 822.7%

Latest on Avacta Group

Our reporting

Next results

22 Apr 2027

Due on 22 Apr 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Avacta Group's ticker?

Avacta Group trades as AVCT.L on LSE, under ISIN GB00BYYW9G87.

What was Avacta Group's last closing price?

59.00p on 20 Nov 2026. The figure is in GBp and is never converted.

When does Avacta Group next report results?

Results are expected on 22 Apr 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.